Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases
Objectives: In recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for dia...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-01-01
|
| Series: | NeuroImage: Clinical |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213158216301863 |
| _version_ | 1819142723498672128 |
|---|---|
| author | Sonja Daerr Matthias Brendel Christian Zach Erik Mille Dorothee Schilling Mathias Johannes Zacherl Katharina Bürger Adrian Danek Oliver Pogarell Andreas Schildan Marianne Patt Henryk Barthel Osama Sabri Peter Bartenstein Axel Rominger |
| author_facet | Sonja Daerr Matthias Brendel Christian Zach Erik Mille Dorothee Schilling Mathias Johannes Zacherl Katharina Bürger Adrian Danek Oliver Pogarell Andreas Schildan Marianne Patt Henryk Barthel Osama Sabri Peter Bartenstein Axel Rominger |
| author_sort | Sonja Daerr |
| collection | DOAJ |
| description | Objectives: In recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for diagnosis of Alzheimer's disease, but there have been few side-by-side studies. Therefore, we investigated the performance of early acquisitions of [18F]-florbetaben (FBB) PET compared to [18F]-fluorodeoxyglucose (FDG) PET in a clinical setting.
Methods: All subjects were recruited with clinical suspicion of dementia due to neurodegenerative disease. FDG PET was undertaken by conventional methods, and amyloid PET was performed with FBB, with early recordings for the initial 10 min (early-phase FBB), and late recordings at 90–110 min p.i. (late-phase FBB). Regional SUVR with cerebellar and global mean normalization were calculated for early-phase FBB and FDG PET. Pearson correlation coefficients between FDG and early-phase FBB were calculated for predefined cortical brain regions. Furthermore, a visual interpretation of disease pattern using 3-dimensional stereotactic surface projections (3D-SSP) was performed, with assessment of intra-reader agreement.
Results: Among a total of 33 patients (mean age 67.5 ± 11.0 years) included in the study, 18 were visually rated amyloid-positive, and 15 amyloid-negative based on late-phase FBB scans. Correlation coefficients for early-phase FBB vs. FDG scans displayed excellent agreement in all target brain regions for global mean normalization. Cerebellar normalization gave strong, but significantly lower correlations. 3D representations of early-phase FBB visually resembled the corresponding FDG PET images, irrespective of the amyloid-status of the late FBB scans.
Conclusions: Early-phase FBB acquisitions correlate on a relative quantitative and visual level with FDG PET scans, irrespective of the amyloid plaque density assessed in late FBB imaging. Thus, early-phase FBB uptake depicts a metabolism-like image, suggesting it as a valid surrogate marker for synaptic dysfunction, which could ultimately circumvent the need for additional FDG PET investigation in diagnosis of dementia. |
| first_indexed | 2024-12-22T12:14:53Z |
| format | Article |
| id | doaj.art-f8b638ef9d4741bea6b28682fcc5b68f |
| institution | Directory Open Access Journal |
| issn | 2213-1582 |
| language | English |
| last_indexed | 2024-12-22T12:14:53Z |
| publishDate | 2017-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | NeuroImage: Clinical |
| spelling | doaj.art-f8b638ef9d4741bea6b28682fcc5b68f2022-12-21T18:26:10ZengElsevierNeuroImage: Clinical2213-15822017-01-0114C778610.1016/j.nicl.2016.10.005Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine casesSonja Daerr0Matthias Brendel1Christian Zach2Erik Mille3Dorothee Schilling4Mathias Johannes Zacherl5Katharina Bürger6Adrian Danek7Oliver Pogarell8Andreas Schildan9Marianne Patt10Henryk Barthel11Osama Sabri12Peter Bartenstein13Axel Rominger14Dept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, GermanyDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, GermanyDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, GermanyDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, GermanyDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, GermanyDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, GermanyISD, Ludwig-Maximilians-Universität München, München, GermanyDept. of Neurology, Ludwig-Maximilians-Universität München, München, GermanyDept. of Psychiatry, Ludwig-Maximilians-Universität München, München, GermanyDept. of Nuclear Medicine, University of Leipzig, Leipzig, GermanyDept. of Nuclear Medicine, University of Leipzig, Leipzig, GermanyDept. of Nuclear Medicine, University of Leipzig, Leipzig, GermanyDept. of Nuclear Medicine, University of Leipzig, Leipzig, GermanyDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, GermanyDept. of Nuclear Medicine, Ludwig-Maximilians-Universität München, München, GermanyObjectives: In recent years several [18F]-labelled amyloid PET tracers have been developed and have obtained clinical approval. There is accumulating evidence that early (post injection) acquisitions with these tracers are equally informative as conventional blood flow and metabolism studies for diagnosis of Alzheimer's disease, but there have been few side-by-side studies. Therefore, we investigated the performance of early acquisitions of [18F]-florbetaben (FBB) PET compared to [18F]-fluorodeoxyglucose (FDG) PET in a clinical setting. Methods: All subjects were recruited with clinical suspicion of dementia due to neurodegenerative disease. FDG PET was undertaken by conventional methods, and amyloid PET was performed with FBB, with early recordings for the initial 10 min (early-phase FBB), and late recordings at 90–110 min p.i. (late-phase FBB). Regional SUVR with cerebellar and global mean normalization were calculated for early-phase FBB and FDG PET. Pearson correlation coefficients between FDG and early-phase FBB were calculated for predefined cortical brain regions. Furthermore, a visual interpretation of disease pattern using 3-dimensional stereotactic surface projections (3D-SSP) was performed, with assessment of intra-reader agreement. Results: Among a total of 33 patients (mean age 67.5 ± 11.0 years) included in the study, 18 were visually rated amyloid-positive, and 15 amyloid-negative based on late-phase FBB scans. Correlation coefficients for early-phase FBB vs. FDG scans displayed excellent agreement in all target brain regions for global mean normalization. Cerebellar normalization gave strong, but significantly lower correlations. 3D representations of early-phase FBB visually resembled the corresponding FDG PET images, irrespective of the amyloid-status of the late FBB scans. Conclusions: Early-phase FBB acquisitions correlate on a relative quantitative and visual level with FDG PET scans, irrespective of the amyloid plaque density assessed in late FBB imaging. Thus, early-phase FBB uptake depicts a metabolism-like image, suggesting it as a valid surrogate marker for synaptic dysfunction, which could ultimately circumvent the need for additional FDG PET investigation in diagnosis of dementia.http://www.sciencedirect.com/science/article/pii/S2213158216301863Alzheimer's diseaseß-amyloid[18F]-florbetaben PETFDG PetMetabolismPerfusion |
| spellingShingle | Sonja Daerr Matthias Brendel Christian Zach Erik Mille Dorothee Schilling Mathias Johannes Zacherl Katharina Bürger Adrian Danek Oliver Pogarell Andreas Schildan Marianne Patt Henryk Barthel Osama Sabri Peter Bartenstein Axel Rominger Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases NeuroImage: Clinical Alzheimer's disease ß-amyloid [18F]-florbetaben PET FDG Pet Metabolism Perfusion |
| title | Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases |
| title_full | Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases |
| title_fullStr | Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases |
| title_full_unstemmed | Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases |
| title_short | Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases |
| title_sort | evaluation of early phase 18f florbetaben pet acquisition in clinical routine cases |
| topic | Alzheimer's disease ß-amyloid [18F]-florbetaben PET FDG Pet Metabolism Perfusion |
| url | http://www.sciencedirect.com/science/article/pii/S2213158216301863 |
| work_keys_str_mv | AT sonjadaerr evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT matthiasbrendel evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT christianzach evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT erikmille evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT dorotheeschilling evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT mathiasjohanneszacherl evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT katharinaburger evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT adriandanek evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT oliverpogarell evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT andreasschildan evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT mariannepatt evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT henrykbarthel evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT osamasabri evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT peterbartenstein evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases AT axelrominger evaluationofearlyphase18fflorbetabenpetacquisitioninclinicalroutinecases |